INDV Healthcare

Indivior Pharmaceuticals, Inc.

$36.28+2.57%

Price as of close on Nov 2, 2026 · Financials updated Oct 9, 2026

Basics

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Country: United States
Market cap: 4.3B USD
Enterprise value: 4.1B USD
Full-time employees: 827

Overall health

Strength: more profitable than most peersmore profitable than peers
Strength: growing faster than most peersgrowing faster than peers
Strength: its shares are priced lower than most peers relative to what it earnspriced lower than peers for its earnings
Drawback: higher risk than most peers: its share price swings more than most peers’ (beta 1.18 vs a peer median of 0.63) and less short-term liquidity (current ratio 0.84 vs a peer median of 2.59)higher risk: bigger price swings (beta 1.18 vs peers 0.63) and less liquidity (current ratio 0.84 vs peers 2.59)

Ranks #156 of 1,157 healthcare companies (top 14%)

See how it ranks against its peers

Worth knowing

Profitable, but burning cash. Reports a profit, but free cash flow is negative.
Indivior Pharmaceuticals reports a profit but its free cash flow is negative: it spent more on investment and running the business than it brought in. That's common for companies building capacity, but it means the profit isn't yet turning into cash.
Paying shareholders without free cash flow. Paid out $217M over the 3 fiscal years to 2025 with -$394M of free cash flow.
Indivior Pharmaceuticals returned $217M in buybacks and dividends over three fiscal years while its free cash flow totalled -$394M. The money came from its cash pile or from borrowing.
Negative shareholders' equity. Liabilities exceed assets on the balance sheet.
Indivior Pharmaceuticals's liabilities exceed its assets on the balance sheet. Large share buybacks can cause this in healthy companies, but so can accumulated losses; either way, debt-based ratios need care.
Investment surge. Capital spending 5.3% of revenue, up from 0.6% in 2022.
Indivior Pharmaceuticals is spending 5.3% of revenue on facilities and equipment, up from 0.6% in 2022. That weighs on free cash flow today; whether it pays off depends on the returns those investments earn.

StockQuotient Score

69/ 100

Oct 5 69 → Nov 4 69

Valuation

Is the price right?

85/100

Strong▼ 1 since Oct 27 close

3/3 inputs reported · High confidence

Since last quarter: ▲ Stronger

Share count down 3.2%

Valuation also moves with the share price every day.

Why it changed since the Oct 27, 2026 close: Score 86 → 85

Share price +4.5%-1

Each step re-scores the company against its peers as they were on Oct 28, 2026; the parts add up to the change. Price effects on EBITDA yield are approximate.

Why

Stronger than most peers on:

▲ Earnings yield
▲ EBITDA yield

Compare with peers

Behind the score

Sector-normalized EBITDA, earnings, and free cash flow yields.

Earnings yield8.3%

SEC filings · 12 months to Jun 2026Reported value30% base weight · Z-score 4.62Sector median: 0.0148 · MAD: 0.0148

EBITDA yield9.5%

SEC filings · 12 months to Jun 2026Reported value50% base weight · Z-score 1.36Sector median: 0.0401 · MAD: 0.0401

Free cash flow yield-2.6%

SEC filings · 12 months to Jun 2026 · operating cash flow − capital spendingNegative (a loss or cash outflow), so it counts as zero whatever the share price20% base weight · Z-score 0.00Sector median: 0.0000 · MAD: 0.0000

Other data (not scored)

Book yield-4.9%

SEC filings · latest balance sheetOutlier capped at sector 5th/95th percentileInformational · 0% composite weightSector median: 0.3716 · MAD: 0.2313

Growth

Is it growing?

88/100

Strong

3/3 inputs reported · High confidence

Since last quarter: ▲ Stronger

12-month revenue up 3.2%

Why

Stronger than most peers on:

▲ EPS growth
▲ Revenue growth
▲ 3-yr revenue

Compare with peers

Behind the score

Revenue and earnings-per-share growth over one year, and revenue growth over three years.

Earnings per share growth248.5%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score 7.98Sector median: 0.0976 · MAD: 0.2991

3-year revenue growth11.2%

Yahoo Finance fallback · SEC figure unavailable or out of date · 3 fiscal years to Dec 2025Reported value33% base weight · Z-score 0.64Sector median: 0.0584 · MAD: 0.0840

Revenue growth13.5%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score 0.76Sector median: 0.0609 · MAD: 0.0974

Profitability

Does it earn well?

98/100

Strong

3/3 inputs reported · High confidence

Since last quarter: ▲ Stronger

Operating margin rose 5.8 points to 31.6%

Why

Stronger than most peers on:

▲ ROA
▲ ROIC
▲ Operating margin

Compare with peers

Behind the score

Return on invested capital, operating margin, and return on assets.

Operating margin31.6%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score 2.02Sector median: 0.0706 · MAD: 0.1217

Return on assets28.9%

SEC filings · 12 months to Jun 2026Outlier capped at sector 5th/95th percentile33% base weight · Z-score 2.47Sector median: 0.0166 · MAD: 0.0537

Return on invested capital583.5%

SEC filings · 12 months to Jun 2026Outlier capped at sector 5th/95th percentile33% base weight · Z-score 3.81Sector median: 0.0471 · MAD: 0.1004

Other data (not scored)

Gross margin82.0%

SEC filings · 12 months to Jun 2026Reported valueInformational · 0% composite weightSector median: 0.4697 · MAD: 0.2310

Return on equityUnavailable

Missing · left out of the scoreInformational · 0% composite weightSector median: 0.0330 · MAD: 0.1225

Risk

Debt, liquidity, price swings

Higher

Higher relative risk

3/3 inputs reported · High confidence

Since last quarter: No major change

Why

Weaker than most peers on:

▼ Debt / equity
▼ Current ratio
▼ Beta

Compare with peers

Behind the score

Relative to sector peers: 0 = lower relative risk · 1 = moderate · 2 = higher. Based on leverage, beta and liquidity.

Beta1.18

Yahoo Finance · 5-year monthly beta vs the marketReported value33% base weight · Z-score -1.63Sector median: 0.6250 · MAD: 0.3380

Current ratio0.84×

SEC filings · latest balance sheetReported value33% base weight · Z-score -1.26Sector median: 2.5860 · MAD: 1.3850

Debt / equityUnavailable

Shareholders' equity is negative, so debt/equity counts as among the highest in its peer group33% base weight · Z-score -9.77Sector median: 0.2215 · MAD: 0.2039

Valuation, growth and profitability scores: higher is better. Risk: 0 is lower, 2 is higher. Risk is a relative proxy, not a bankruptcy probability. Scores depend on available sector peers.

Questions investors ask about Indivior Pharmaceuticals

Is Indivior Pharmaceuticals getting weaker?: Its latest SEC filing (Aug 3, 2026) got stronger: operating margin rose 5.8 points to 31.6%; share count down 3.2%. Its overall score is unchanged at 69/100 since Oct 28, 2026.
How is Indivior Pharmaceuticals valued vs its peers?: Priced lower than most peers relative to what it earns. Valuation scores 85/100 against 1,393 healthcare peers. Earnings yield 8.3% vs a peer median of 1.5% (stronger than 91% of peers).Earnings yield 8.3% vs peers 1.5% (stronger than 91% of peers).
Is Indivior Pharmaceuticals growing?: Yes, faster than most of its peers. Growth scores 88/100 against 1,393 healthcare peers. Earnings per share growth 248.5% vs a peer median of 9.8% (stronger than 96% of peers).Earnings per share growth 248.5% vs peers 9.8% (stronger than 96% of peers).
How profitable is Indivior Pharmaceuticals?: More profitable than most of its peers. Profitability scores 98/100 against 1,393 healthcare peers. Return on assets 28.9% vs a peer median of 1.7% (stronger than 95% of peers).Return on assets 28.9% vs peers 1.7% (stronger than 95% of peers).
How risky is Indivior Pharmaceuticals?: Higher risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Current ratio 0.84× vs a peer median of 2.59× (weaker than 94% of peers).Current ratio 0.84× vs peers 2.59× (weaker than 94% of peers). A relative measure, not a bankruptcy probability.

Latest filing: what changed

Quarter ended Jun 30, 2026 · filed Aug 3, 2026 · compared with the quarter ended Mar 31, 2026

Got stronger

Operating margin rose 5.8 points to 31.6%
Share count down 3.2%

	Previous quarter	Latest quarter	Change
Revenue (12 months)	1.3B USD	1.3B USD	+3.2%
Net income (12 months)	252.0M USD	356.0M USD	+41.3%
Operating margin	25.8%	31.6%	+5.8 pts
Free cash flow (12 months)	−192.0M USD	−111.0M USD	−42.2%
Debt	486.0M USD	487.0M USD	+0.2%
Cash	175.0M USD	222.0M USD	+26.9%
Shares outstanding	121.9M	118.0M	−3.2%

From the company’s own SEC filings, as filed. Twelve-month figures roll forward one quarter at a time.

Industry valuation context

Industry: Drug Manufacturers - Specialty & Generic · 27 companies

Valuations in Drug Manufacturers - Specialty & Generic are within their usual range since Jun 2020.

45% of months since Jun 2020 were valued lower than now.
24% of companies are in the most expensive fifth of their own price-to-sales history.
Median price-to-sales is +8% vs the whole market, against a usual +36%.

Jun 2020Shaded: most expensive fifth of its range2026

Financials

Fiscal years from SEC annual filings · change vs the prior year

Key ratios	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	Change
Gross margin	83.9%	83.1%	84.1%	80.6%	80.2%	▼ 0.3 pts
Operating margin	26.9%	-9.0%	-13.9%	3.2%	21.1%	▲ 18 pts
Net margin	25.9%	-4.9%	-11.5%	0.6%	16.9%	▲ 16 pts
Return on assets (ROA)	11.2%	-2.5%	-7.2%	0.5%	17.5%	▲ 17 pts
Return on equity (ROE)	169.4%	—	—	—	—	—
Free cash flow margin	44.1%	-1.0%	-28.2%	0.6%	-7.5%	▼ 8.1 pts
Current ratio	1.80×	1.24×	0.98×	0.90×	0.71×	▼ 20%
Quick ratio	1.68×	1.12×	0.88×	0.71×	0.55×	▼ 24%
Debt to equity	2.61×	—	—	—	—	—
Interest coverage	7.89×	-3.00×	-4.34×	0.93×	5.82×	▲ 528%

INDV price history

Price history is added with the daily price update and will appear after the next one.

Similar companies

Sector leaderboards

BB Biotech AGBBZA.DE100/ 100

Arbutus Biopharma CorporationABUS97/ 100

Q32 Bio Inc.QTTB97/ 100

Bringing the fundamentals into focus…

Overall health

Strength: more profitable than most peersmore profitable than peers

Strength: growing faster than most peersgrowing faster than peers

Strength: its shares are priced lower than most peers relative to what it earnspriced lower than peers for its earnings

Drawback: higher risk than most peers: its share price swings more than most peers’ (beta 1.18 vs a peer median of 0.63) and less short-term liquidity (current ratio 0.84 vs a peer median of 2.59)higher risk: bigger price swings (beta 1.18 vs peers 0.63) and less liquidity (current ratio 0.84 vs peers 2.59)

Ranks #156 of 1,157 healthcare companies (top 14%)

See how it ranks against its peers

Worth knowing

Profitable, but burning cash. Reports a profit, but free cash flow is negative.

Indivior Pharmaceuticals reports a profit but its free cash flow is negative: it spent more on investment and running the business than it brought in. That's common for companies building capacity, but it means the profit isn't yet turning into cash.

Paying shareholders without free cash flow. Paid out $217M over the 3 fiscal years to 2025 with -$394M of free cash flow.

Indivior Pharmaceuticals returned $217M in buybacks and dividends over three fiscal years while its free cash flow totalled -$394M. The money came from its cash pile or from borrowing.

Negative shareholders' equity. Liabilities exceed assets on the balance sheet.

Indivior Pharmaceuticals's liabilities exceed its assets on the balance sheet. Large share buybacks can cause this in healthy companies, but so can accumulated losses; either way, debt-based ratios need care.

Investment surge. Capital spending 5.3% of revenue, up from 0.6% in 2022.

Indivior Pharmaceuticals is spending 5.3% of revenue on facilities and equipment, up from 0.6% in 2022. That weighs on free cash flow today; whether it pays off depends on the returns those investments earn.

Questions investors ask about Indivior Pharmaceuticals

Is Indivior Pharmaceuticals getting weaker?

Its latest SEC filing (Aug 3, 2026) got stronger: operating margin rose 5.8 points to 31.6%; share count down 3.2%. Its overall score is unchanged at 69/100 since Oct 28, 2026.

How is Indivior Pharmaceuticals valued vs its peers?

Priced lower than most peers relative to what it earns. Valuation scores 85/100 against 1,393 healthcare peers. Earnings yield 8.3% vs a peer median of 1.5% (stronger than 91% of peers).Earnings yield 8.3% vs peers 1.5% (stronger than 91% of peers).

Is Indivior Pharmaceuticals growing?

Yes, faster than most of its peers. Growth scores 88/100 against 1,393 healthcare peers. Earnings per share growth 248.5% vs a peer median of 9.8% (stronger than 96% of peers).Earnings per share growth 248.5% vs peers 9.8% (stronger than 96% of peers).

How profitable is Indivior Pharmaceuticals?

More profitable than most of its peers. Profitability scores 98/100 against 1,393 healthcare peers. Return on assets 28.9% vs a peer median of 1.7% (stronger than 95% of peers).Return on assets 28.9% vs peers 1.7% (stronger than 95% of peers).

How risky is Indivior Pharmaceuticals?

Higher risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Current ratio 0.84× vs a peer median of 2.59× (weaker than 94% of peers).Current ratio 0.84× vs peers 2.59× (weaker than 94% of peers). A relative measure, not a bankruptcy probability.

Previous quarter

Latest quarter

Change

Revenue (12 months)

1.3B USD

1.3B USD

+3.2%

Net income (12 months)

252.0M USD

356.0M USD

+41.3%

Operating margin

25.8%

31.6%

+5.8 pts

Free cash flow (12 months)

−192.0M USD

−111.0M USD

−42.2%

Debt

486.0M USD

487.0M USD

+0.2%

Cash

175.0M USD

222.0M USD

+26.9%

Shares outstanding

121.9M

118.0M

−3.2%

Key ratios

FY 2021

FY 2022

FY 2023

FY 2024

FY 2025

Change

Gross margin

83.9%

83.1%

84.1%

80.6%

80.2%

▼ 0.3 pts

Operating margin

26.9%

-9.0%

-13.9%

3.2%

21.1%

▲ 18 pts

Net margin

25.9%

-4.9%

-11.5%

0.6%

16.9%

▲ 16 pts

Return on assets (ROA)

11.2%

-2.5%

-7.2%

0.5%

17.5%

▲ 17 pts

Return on equity (ROE)

169.4%

—

Free cash flow margin

44.1%

-1.0%

-28.2%

0.6%

-7.5%

▼ 8.1 pts

Current ratio

1.80×

1.24×

0.98×

0.90×

0.71×

▼ 20%

Quick ratio

1.68×

1.12×

0.88×

0.71×

0.55×

▼ 24%

Debt to equity

2.61×

—

Interest coverage

7.89×

-3.00×

-4.34×

0.93×

5.82×

▲ 528%